We tested the hypothesis that a centrally administered a,-receptor agonist could alter the cerebrovascular response to hypoxia, without evidence of systemic absorption of the drug. Beagle dogs were anesthetized with 1.4% isoflurane and exposed to hypoxic hypoxia (Pao, approximately 22 mm Hg) before and after ventricular-cisternal perfusion with mock cerebrospinal fluid (CSF group, n = 5) or dexmedetomidine (100 pg/mL; total dose 300 Kg; DEX group, rz = 6). Cerebral perfusion pressure, Pace, and arterial oxygen content were controlled and regional cerebral blood flow (CBF; microspheres) and global cerebral metabolic rate for oxygen consumption (CMRO,) were measured. In another group (n = 5), drug distribution under the experimental conditions was assessed by 3H-clonidine administered by ventricular-cisternal perfusion. In the mock CSF group, flow to the cerebral hemispheres increased during hypoxia under baseline conditions and after CSF infusion: 66 2 8 to 170 ? 15 mL * min-' * 100 g-i (265% -C 24% of baseline value), 83 t 9 to 154 t 14 mL * mini * 100 ggi (201% ? 54% of post-CSF infusion value). DEX decreased normoxie flow in the cerebral hemispheres from 76 ? 6 to 44*4ml*min-l* 100 g-' with decreases in other regions of similar magnitude.
We tested the hypothesis that a centrally administered a,-receptor agonist could alter the cerebrovascular response to hypoxia, without evidence of systemic absorption of the drug. Beagle dogs were anesthetized with 1.4% isoflurane and exposed to hypoxic hypoxia (Pao, approximately 22 mm Hg) before and after ventricular-cisternal perfusion with mock cerebrospinal fluid (CSF group, n = 5) or dexmedetomidine (100 pg/mL; total dose 300 Kg; DEX group, rz = 6). Cerebral perfusion pressure, Pace, and arterial oxygen content were controlled and regional cerebral blood flow (CBF; microspheres) and global cerebral metabolic rate for oxygen consumption (CMRO,) were measured. In another group (n = 5), drug distribution under the experimental conditions was assessed by 3H-clonidine administered by ventricular-cisternal perfusion. In the mock CSF group, flow to the cerebral hemispheres increased during hypoxia under baseline conditions and after CSF infusion: 66 2 8 to 170 ? 15 mL * min-' * 100 g-i (265% -C 24% of baseline value), 83 t 9 to 154 t 14 mL * mini * 100 ggi (201% ? 54% of post-CSF infusion value). DEX decreased normoxie flow in the cerebral hemispheres from 76 ? 6 to 44*4ml*min-l* 100 g-' with decreases in other regions of similar magnitude.
After DEX, the absolute flow in all regions during hypoxia was 52%-55% of that prior to DEX (P < 0.05). However, because DEX also decreased normoxic CBF, the percent increase in flow during hypoxia was similar before and after DEX. CMRO, was not affected by hypoxia prior to DEX. However, after DEX, hypoxia caused a marked reduction in cerebral oxygen delivery (5.2 + 1.0 vs 13.7 ? 2.3 ml * mine1 * 100 g-i for the CSF group) and CMRO, (2.5 ? 0.6 vs 3.9 ? 0.6 ml * min-' * 100 g-l). Regional accumulation of intraventricularly administered 3H-clonidine was greatest in periventricular brain structures (e.g., caudate nucleus, dorsal brainstem), and the concentration in the cerebral cortex was approximately 1% of the concentration in the ipsilateral caudate nucleus. We conclude that centrally administered DEX reduces CBF during normoxia and prevents adequate oxygen delivery during hypoxia. The mechanism of DEX-induced CBF reduction is not metabolically mediated, since CMRO, is maintained at control values during normoxia despite the significant blood flow reduction. We believe that the reduction in CMRO, during hypoxia in DEX-treated dogs is the result of a reduction of oxygen delivery rather than the underlying mechanism for the observed reduction in CBF during hypoxia. (Anesth Analg 1997; 84:13947) S ystemic administration of crz agonists causes sedation (l), decreases global cerebral blood flow (CBF) (2), and limits hypercapniaand hypoxiainduced cerebral vasodilation (3, 4 
Methods
This study was approved by our animal care and use committee. Nineteen beagle dogs (9-11 kg) were anesthetized with thiopental12 mg/ kg intravenously (IV), endotracheally intubated, and the lungs mechanically ventilated (Harvard respirator pump; Harvard Apparatus Co., South Natick, MA). Oxygen was administered to maintain Pao, greater than 90mm Hg and isoflurane was administered in the inspiratory limb of the ventilator circuit by an isoflurane vaporizer (Ohio Medical Products, Model TC-3, Madison, WI). Endtidal isoflurane was monitored with an infrared analyzer designed for halogenated drugs (Nelcor 2500; Nelcor Inc., Haywood, CA) and the end-tidal isoflurane concentration was maintained at 1.4%. A single dose of pancuronium bromide (0.1 mg/kg, IV bolus) was administered to minimize muscle contraction from electrocautery in all animals. A catheter was placed retrograde via a femoral artery into the left ventricle for radiolabeled microsphere injection. Bilateral omocervical artery catheters were inserted and advanced into the aortic arch for measurement of mean arterial blood pressure (MABP), withdrawal of microsphere reference blood, and arterial blood gas analysis. Bilateral femoral vein catheters were placed for rapid removal of blood to prevent increases in cerebral perfusion pressure (CPP=MABP-sagittal sinus pressure) during administration of hypoxic gas mixtures.
The animal was turned prone and the head fixed in a head holder elevated 10 cm above midthoracic level. A catheter was placed in the sagittal sinus for withdrawal of cerebral venous blood and measurement of sagittal sinus pressure. A 3-mm craniectomy was performed 3-4 mm lateral to the midline and immediately anterior to the coronal suture over the left hemisphere. A 2.5-mm silicone elastic ventricular drain (Cordis, Miami, FL) was advanced l-2 cm into the lateral ventricle after a dural incision. Location of the drain tip in the lateral ventricle was indicated by return of clear cerebrospinal fluid (CSF). Drain location was further verified by a rapid decrease of pressure in the lateral ventricle when CSF was allowed to escape from a catheter placed in the cisterna magna. Arterial and sagittal sinus pressure transducers were referenced to the right atrium. The lateral ventricular pressure and sagittal sinus pressure transducers were referenced to the level of the external auditory meatus. CBF was measured with radiolabeled microspheres (15 t 0.5 pm diameter; DuPont-NEN Products; Boston, MA) using the reference withdrawal method. Six radiolabels were used and injected in random sequence (153Gd, 'i41n, i13Sn, io3Ru, 95Nb, 46Sc). Regional flow was determined in cerebral hemispheres, caudate nucleus, brainstem, cerebellum, and cerebral cortex (1 X 1 X10-mm superficial slice from parietal lobe).
The central distribution of a drug administered according to the techniques of this study were assessed by determining the distribution of radioactivity produced after ventricular-cisternal administration of 3H-clonidine, also an CY~ agonist, but less lipid soluble. Tritiated DEX was unavailable at the time of this study and a less soluble tracer was chosen to maximize diffusion through the CSF space. Tissue samples for 3H-clonidine measurement were stored at -70°C and homogenized in 0.32 M sucrose prior to analyses. An aliquot of 100 PL of tissue homogenate was used to quantify 3H-clonidine by liquid scintillation spectroscopy (Beckman Instruments, Model LS 1800, Fullerton, CA). Protein content of the homogenates was assayed by the method of Bradford (10) with bovine serum albumin as the protein standard.
Surgical preparation required approximately 45 min. During 15 min of stabilization the intraventricular drain was used for administration of 2 mL mock CSF (11) over 5 min. This was followed by a continuous infusion of mock CSF at 0.2 mL/min into the lateral ventricular catheter.
In three animals, the effect of DEX concentration and specificity of effect by reversal with a highly specific (Ye antagonist, atipamezole, were determined. After determination of baseline data, all variables were recorded after the ventriculocisternal perfusion was sequentially switched to DEX in concentrations of 1, 10, and 100 pg/mL. After the last infusion of DEX, an intraventricular infusion containing atipamezole 1000 pg/mL was administered.
As with DEX, atipamezole was administered as 2 mL over 5 min and then an infusion at 0.2 mL/min was continued for 10 min. All variables were recorded near the end of the lo-min infusion period to assess the effect on CBF changes produced by the previously administered DEX or atipamezole.
In the hypoxic studies (n = 11) baseline measurements were obtained after 1 h of anesthesia at normoxia (15 min of mock CSF infusion). During lateral ventricular mock CSF infusion, isocapnic hypoxia was then produced by introducing nitrogen into the breathing circuit. All measurements were repeated 10 min after obtaining an inspired oxygen concentration of approximately 7%. The nitrogen was then discontinued and a third set of measurements obtained 15 min after reestablishing normoxia. The intraventricular infusion was then changed to either mock CSF (same as initial infusion; n = 5) or DEX (100 pg/mL dissolved in mock CSF; M = 6) with the initial 2 mL administered over 5 min. DEX and atipamezole were provided by Farmos Corp. (Turku, Finland) . A fourth measurement was made 10 min after the initiation of DEX (DEX group) or mock CSF administration (CSF group). During lateral ventricular mock CSF or DEX infusion, isocapnic hypoxia was then produced by introducing nitrogen into the breathing circuit. All measurements were repeated 10 min after obtaining an inspired oxygen concentration of approximately 7%. The nitrogen was then discontinued and a sixth set of measurements obtained 15 min after reestablishing normoxia. In both groups, increases in CPP due to hypoxia were prevented by removal of blood into heparin-treated syringes. At the end of each experiment, the animal was killed with IV KC1 and the brain harvested for subsequent analysis of regional CBF.
In an additional group of animals (CLONIDINE; n = 5), distribution of intraventricular infusion of a tritiated labeled tracer was assessed by infusion of 3H-clonidine (Sigma Chemical Co., St. Louis, MO). 3H-clonidine (0.32 pg / mL; 20 PCi / mL) was dissolved in mock CSF. Two milliliters of the solution was infused over 5 min into the lateral ventricular catheter followed by an infusion of 0.2 mL/min for 30 min to mimic the total infusion time in the other two groups (i.e., from the start of the infusion to the end of hypoxia). During the infusion, the animals were maintained normothermic, normoxic, normocapnic, and normotensive. At the end of the infusion, the animal was killed with IV KC1 and the brain rapidly removed and samples of regions similar to those in which CBF was measured were frozen for later analysis. In particular, samples were taken from regions adjacent to the CSF space and regions distant from the CSF space (cerebral hemisphere contralateral to the infusion site) as well as brainstem and cerebellum. Radioactivity for each sample was normalized to activity in the ipsilatera1 caudate nucleus, which was the region expected to have the highest number of counts per milligram of protein.
Two-way analysis of variance for between (group) and within (time) subjects design was used to compare total and regional CBF, blood gas, and hemodynamic variables during the measurement periods. P < 0.05 was considered significant. If a significant group X time interaction was demonstrated, one-way analysis of variance was performed for between group effects at individual time points and for within group effects (repeated measures). The Student-NewmanKeul's test was used to correct for multiple comparisons. Because SD increased with the mean value during hypoxia, a logarithmic transformation was performed on regional CBF data, prior to data analysis. Data in text, tables and figures are presented as mean 5 SE.
Results
Figure 1 shows regional CBF in cerebellum, brainstem, and cerebrum after ventriculocisternal perfusion of DEX 1, 10, and 100 pg/mL and atipamezole 1000 pg/ mL. In all three regions, there was a progressive decrease in flow with increasing concentrations of DEX with return to flow to baseline level with atipamezole infusion. In all animals, CPP and arterial blood gases were maintained at baseline level throughout the experiment (data not shown). Table 1 shows hemodynamic values in CSF and DEX groups during both episodes of hypoxia. During hypoxia a similar amount of blood was withdrawn (approximately 20 mL / kg) to prevent changes in CPP in each group. Therefore, CPP was similar between groups at each measurement point. Intraventricular infusion of DEX did not require withdrawal of blood and did not result in a change in CPP. Table 2 shows blood gas values in CSF and DEX groups throughout the protocol. Paoz, Pace, and arterial oxygen content were similar in the two groups at each stage of the study. Within each group, the values were also similar during the two hypoxic challenges. Baseline O2 extraction was 0.24 ? 0.04 and 0.23 + 0.02 in CSF and DEX groups, respectively. In both groups, 0, extraction increased with the initial hypoxia (0.36 -+ 0.03 and 0.44 2 0.06, respectively). Oxygen extraction after DEX (prior to the second exposure to hypoxia) was 0.36 + 0.02, which was greater than in CSF group after administration of mock CSF (prior to the second episode of hypoxia). Although extraction increased in both groups during the second episode of hypoxia, the extraction was higher in the DEX group (0.50 2 0.04 vs 0.31 2 0.03; P < 0.05).
Baseline CMRO* in CSF and DEX groups was 3.5 & 0.3 and 3.6 2 0.2 ml * min-' * 100 g-l, respectively. CMRO, was similar in the two groups at all periods of study except for a lower value during the second hypoxic challenge in the DEX group (3.9 ? 0.4 vs 2.5 ? 0.4 ml . mix--' * 100 g-i; P < 0.05). Table 3 shows flow to cerebellum, brainstem, caudate nucleus, cerebral hemispheres, and cerebral cortex in CSF and DEX groups. During baseline conditions, hypoxia increased flow to each of these regions. After recovery from hypoxia, DEX decreased normoxie flow in each region except the cerebellum. Although CBF increased in response to hypoxia in each region during DEX infusion, CBF values obtained during the second hypoxia challenge were significantly lower than those measured during the first hypoxic challenge. Figure 2 shows CVR in CSF and DEX groups. Baseline CVR was similar in the two groups (1.5 + 0.2 and 1.2 t 0.2 mL . min? * mm Hg . 100 g, respectively). The absolute change in CVR during the first hypoxia challenge was not statistically different between groups (CSF group 1.0 ? 0.2; DEX group 0.6 + 0.2 mL * mir-' * mm Hg * 100 g). DEX increased CVR from 1.2 + 0.1 to 2.0 + 0.2mL * rnir-' * mm Hg * 100 g. In both groups, the second hypoxia challenge decreased CVR, but the CVR was higher in the DEX group during hypoxia. The absolute change in CVR during hypoxia was not affected by DEX administration (first hypoxia challenge for DEX group, 0.6 + 0.2; second hypoxia challenge for DEX group, 0.9 t 0.2 mL . rnir? * mm Hg * 100 8-l decrease). Figure 3 shows cerebral oxygen transport in CSF and DEX groups. In the CSF group, baseline cerebral oxygen transport was 14.0 + 2.1 mL * mine1 * 100 g-i and was unchanged as a result of hypoxia or the second administration of mock CSF. In the DEX group, the initial hypoxia slightly decreased cerebral oxygen transport from 14.4 5 1.0 to 10.3 t 2.0 mL * min-' . 100 g-' (P < 0.05). However, DEX administration resulted in a substantial downward and parallel shift in the response to hypoxia. Figure 4 shows brain distribution of 3H-clonidine after its infusion into the left ventricular catheter for 30 min. Activity in the left caudate nucleus was used as a standard. As compared to the left caudate nucleus, activity was the highest in the choroid plexus. The tissue concentration in the cerebral cortex was approximately 1% of that found in the left caudate nucleus. In two animals, the concentration in the infused solution and in CSF collected from the cisterna magna catheter was assessed. The ratio of CSF to infused solution was 19% and 33%, respectively. Figure 5 shows CBF, expressed as a percentage of the normoxic flow, in regions found to have high penetration of cz2 agonist (e.g., caudate nucleus and brainstem) and a region found to have low penetration of CQ agonist (e.g., cerebral cortex) as depicted in Figure 4 . DEX did not influence the percentage increase in flow during In all regions, the flow during the second hypoxi a was less than during the initial hypoxi a (P < 0.05) i n the DEX group.
hypoxia, regardless of the degree of a,-agonist penetration in any region. The hyperemic response to hypoxia was most robust in brainstem as compared to the other regions.
Discussion
During normoxia, ventricular-cisternal perfusion of DEX decreased blood flow throughout the brain without evidence of reduced CMRO,. The lack of blood pressure response to ventricular-cisternal perfusion of DEX suggests that the DEX does not have its effect as a result of systemic absorption of this o2 agonist. Concentration effect and qreceptor specificity were demonstrated in a separate group of animals. To minimize time for diffusion through the CSF space and bulk absorption via the brain capillaries we used, a short exposure time to ventriculocisternal perfusion. To determine the likely cerebral distribution of DEX during ventricular-cisternal perfusion we measured the distribution of another 01~ agonist 3H-clonidine using an identical mode of administration. We found the highest 3H-activity in regions ipsilateral to the ventricular injection and along the pathway to the cisternal outflow. Cerebral cortex demonstrated only approximately 1% of the 3H-activity in the ipsilateral caudate nucleus, but both of these regions had similar reduction in blood flow during ventricular-cisternal perfusion of DEX. Therefore, it is unlikely that DEX mediates a reduction in CBF by activating local vascular '(Y* receptors. Ventricular-cisternal perfusion of DEX was associated with a higher CVR during hypoxia than in control animals. However, the percent increase in CBF and the absolute change in CVR during hypoxia were not decreased in the DEX as compared to the control group. Treatment with DEX reduced cerebral oxygen delivery, both during normoxia and hypoxia. During hypoxia, DEX-induced reduction in cerebral oxygen delivery was severe enough to decrease CMRO,.
Systemic administration of the 01~ agonist DEX results in sedation (l), a decrease in CBF and a transient decrease in intracranial pressure (12) without a change in CMRO, (2,13). Urethane, another (Ye agonist (14), has been studied less well in regard to its effect on CBF and CMRO, but it is widely used in experimental animal models as a baseline anesthetic (usually in combination with or-chloralose). Binding sites for (Ye agonists are most highly concentrated in areas of brain involved in control of cardiovascular function (7). Cerebral arteries are enriched with postsynaptic (Ye adrenoceptors (15) which, when stimulated, cause vasoconstriction (16). The effector mechanism for vasoconstriction and sedation from stimulation of (Ye adrenoceptors appears to involve inhibitory G proteins (17) with inhibition of adenylate cyclase and decreased accumulation of cyclic adenosine monophosphate (18). If the mechanism of blood flow reduction in our study was related to direct vascular effect we would have expected greater effect on blood flow to the regions with the highest concentration of c+ agonist. However, in our study, the blood flow effect was similar in regions (e.g., ipsilateral caudate) found to have a very high concentration of ay2 agonist (3H-clonidine in our study) compared to regions having very low concentration of (~z agonist (e.g., that contralateral cortex) during lateral ventricular infusion. In addition, others have found that the effect on blood flow is not mediated by a change in pial vessel diameter (19) .
The mechanism for the widespread reduction in normoxic CBF during ventricular-cisternal perfusion of DEX appears to be related to its effect on either a subcortical or brainstem structure, as distribution of 3H-clonidine was greatest in these areas. Since DEX is more lipid soluble than clonidine (20), the distribution of 3H-clonidine probably overestimates the spread through the CSF space during the time assessed. In addition,
we believe that it is unlikely that the ventricular-cisternal perfusion of DEX resulted in significant absorption of DEX into the systemic circulation because DEX administration in our study lacked the increase in MABP which is normally present during its systemic administration (3,4). Pharmacodynamic variables relevant to DEX loss from CSF (20) can be used to estimate the maximum systemic absorption of DEX over the period from the start of administration until a global decrease in CBF is demonstrated.
Using pharmacodynamic variables (20) and assuming an intracerebral CSF volume of 7 mL in the dog (21), maximum absorption of the administered dose of DEX (100 pg/mL X mL plus 0.2 mL/ min X 5 min; 300 pg) would be approximately 2.2% (6.5 pg). Since the volume of distribution of DEX is thought to be similar to fentanyl [300 L/70 kg; (20) ], the volume of distribution in a lo-kg beagle would approximate 40 L. The resulting serum level would be approximately two orders of magnitude lower than the serum level previously demonstrated to result from an infusion of 2 pg/ kg administered IV over the same time course (21) and to cause an increase in MABP of 22%. These data, coupled with our demonstration that intraventricular DEX produced no effect on MABP, strongly suggest that the effect of DEX on the cerebral circulation was centrally mediated.
In unanesthetized rabbits, stimulation of peripheral sympathetic nerves limits hypoxia-induced cerebral hyperemia in cerebrum by 13% but has no effects during normoxia (22). We found that CBF during hypoxia was 45% less with ventricular administration of DEX. This suggests that either DEX is more potent that sympathetic stimulation of a more central pathway (unlike electrical sympathetic stimulation), or the level of basal vasodilation was greater in the isofluraneanesthetized animals in the present study than in the unanesthetized animals in the previous study (22) .
There are at least two candidate areas in brainstem that may mediate the effect of DEX on the CBF response to hypoxia: locus coeruleus and rostra1 ventrolateral medulla. Others have found that intraventricular injection of (~z agonist alters neuronal response of the locus coeruleus (23) and in the rostra1 ventrolateral medulla (24). Stimulation of the rostra1 ventrolateral medulla, which has projections to the locus coeruleus, increases regional CBF (134%-169%) but not regional metabolism (25) . Lesions of the rostra1 ventrolateral medulla substantially attenuate hypoxia-induced cerebral hyperemia without affecting hypercapniainduced cerebral hyperemia (25). Therefore, because we have previously demonstrated that CBF during hypercapnia was lower after IV DEX administration (3), we believe that it is unlikely that the effect of DEX is at the rostra1 ventrolateral medulla. Likewise, our data do not completely support the hypothesis that DEX is producing a reduction in CBF via a mechanism which involves stimulation of the locus coeruleus, as electrical stimulation of the locus coeruleus produces a reduction in CBF which is linked to a reduction in CMRO, (26) .
An important consideration is whether the lower flows during hypoxia in the present study is somehow metabolically mediated. For example, large-dose barbiturate anesthesia, which reduces CMRO,, is associated with attenuated hypoxia-induced cerebral hyperemia (27). We do not believe that DEX produced a metabolically mediated reduction in hypoxia-induced hyperemia because DEX did not reduce CMRO, under baseline conditions. On the contrary, CMRO, was only reduced by DEX during hypoxia. Therefore, we believe that the reduction in CMRO, during hypoxia from DEX administration is due to a drug-induced reduction of oxygen delivery (reduced oxygen content of blood during a period of nonmetabolically induced CBF reduction) to the point of tissue hypoxia.
Reduction of CBF during hypoxia, to the point of causing a reduction in CMRO, during hypoxia after treatment with DEX, may have important clinical implications.
DEX is presently being evaluated as an anesthetic adjunct in clinical anesthesiology (1,lS). If administration of DEX causes inadequate oxygen delivery during a period of hypoxia, its clinical safety may be in question. Further studies must be performed to determine whether DEX administration will result in more rapid decline of high-energy phosphates with cerebral lactic acidosis during a period of hypoxia.
Although DEX in combination with hypoxic hypoxia results in tissue hypoxia in the current study, the literature suggests that DEX may be neuroprotective in the setting of ischemia. The literature concerning the effect of a,-receptor agonists and antagonists in immediate postischemic administration of idazoxan, an ar,-receptor antagonist, ameliorated brain injury in rats exposed to transient forebrain ischemia (32,331. The mechanism of protection has been proposed to be related to accentuated catecholamine release within brain (32,34). The rationale for why both an a,-receptor agonist and an antagonist have therapeutic effects in the setting of cerebral ischemia has not been resolved.
In conclusion, we have found that central administration of the (Ye agonist DEX increases cerebrovascular tone during normoxia and severe hypoxia, without evidence of systemic absorption of the drug. DEX-induced vasoconstriction is sufficiently robust to limit cerebral oxygen delivery during hypoxia and result in reduced CMRO,.
Although the amount of cerebral vascular tone during hypoxia is greater in dogs pretreated with DEX, the absolute change in tone resulting from hypoxia is unaltered by DEX. Therefore, we do not believe that DEX alters the underlying mechanism for the cerebrovascular response to hypoxia.
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